🇺🇸 FDA
Patent

US 12291508

Hydrazide containing nuclear transport modulators and uses thereof

granted A61KA61K31/4196A61K31/4439

Quick answer

US patent 12291508 (Hydrazide containing nuclear transport modulators and uses thereof) held by Karyopharm Therapeutics Inc. expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Karyopharm Therapeutics Inc.
Grant date
Tue May 06 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K31/4196, A61K31/4439, A61K31/454, A61K31/496